CAR T Cells Targeting SIGLEC15 for Solid Tumor Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer treatment methods, including surgery, radiotherapy, chemotherapy, targeted therapy, and immunotherapy, often fail to effectively treat advanced cancer patients and are associated with significant side effects and a poor quality of life.
Innovation Solution
The development of chimeric antigen receptor (CAR) cells that specifically target antigens such as SIGLEC15, SLC6A3, KISS1R, QRFPR, GPR119, CLDN6, UPK2, ADAM12, SLC45A3, ACPP, MUC21, MUC16, MS4A12, ALPP, and others, which are differentially expressed on solid tumor cells and normal tissues, allowing for targeted cancer therapy with reduced harm to normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional cancer treatments (surgery, radiotherapy, chemotherapy, targeted therapy, immunotherapy) are used, then cancer cells can be treated, but normal tissues are damaged causing side effects and poor quality of life
Solution Approach 1:
The CAR cell therapy applies local quality by engineering T cells to express chimeric antigen receptors that specifically recognize and bind to tumor-associated antigens. This creates a localized and specific immune response against cancer cells while sparing normal tissues that do not express these antigens, thereby resolving the contradiction between treatment effectiveness and normal tissue damage
Solution Approach 2:
The CAR cell acts as an intermediary between the immune system and tumor cells. The engineered T cells with specific antigen receptors serve as mediators that selectively target cancer cells expressing tumor-associated antigens, enabling precise cancer cell destruction without the non-specific tissue damage caused by conventional therapies
2Reliability
If CAR cells targeting differentially expressed antigens are used, then cancer cell killing is enhanced, but the risk of harming normal cells expressing these antigens remains
Solution Approach 1:
The patent applies parameter changes by selecting antigens with specific expression patterns - tumor-associated antigens that are differentially expressed on cancer cells compared to normal tissues. This parameter difference in antigen expression levels enables the CAR cells to preferentially target and kill cancer cells while minimizing harm to normal cells that express these antigens at lower or undetectable levels
Data Source
AI summary
The compositions and methods described herein are directed to treating solid tumor using CAR T therapy. The compositions include CAR comprising an extracellular domain that binds a siglec protein or a receptor that binds the peptide hormone kisspeptin.